Drug Standards
- (2)
- (4)
- (1)
- (3)
- (3)
- (665)
- (3)
- (27)
- (1)
- (6)
- (27)
- (61)
- (24)
- (1)
- (2)
- (35)
- (367)
- (45)
- (1)
- (2)
- (1)
- (5)
- (5)
- (4)
- (2)
- (7)
- (1)
- (5)
- (4)
- (3)
- (3)
- (1)
- (3)
- (2)
- (2)
- (1)
- (3)
- (4)
- (2)
- (2)
- (1)
- (1)
- (3)
- (1)
- (1)
- (4)
- (1)
- (1)
- (1)
- (4)
- (3)
- (1)
- (1)
- (2)
- (5)
- (1)
- (2)
- (4)
- (1)
- (3)
- (5)
- (3)
- (1)
- (2)
- (1)
- (3)
- (1)
- (1)
- (3)
- (4)
- (2)
- (2)
- (1)
- (4)
- (4)
- (5)
- (3)
- (1)
- (1)
- (1)
- (1)
- (1)
- (1)
- (1)
- (1)
- (1)
- (1)
- (1)
- (3)
- (4)
- (3)
- (1)
- (2)
- (1)
- (2)
- (1)
- (5)
- (2)
- (2)
- (1)
- (5)
- (7)
- (3)
- (1)
- (1)
- (1)
- (4)
- (3)
- (1)
- (4)
- (1)
- (8)
- (2)
- (1)
- (5)
- (13)
- (1)
- (2)
- (1)
- (1)
- (1)
- (2)
- (4)
- (1)
- (5)
- (1)
- (1)
- (2)
- (1)
- (6)
- (2)
- (1)
- (2)
- (1)
- (3)
- (2)
- (1)
- (3)
- (3)
- (1)
- (1)
- (2)
- (3)
- (1)
- (1)
- (1)
- (2)
- (4)
- (3)
- (1)
- (1)
- (5)
- (3)
- (2)
- (5)
- (1)
- (3)
- (1)
- (1)
- (1)
- (1)
- (1)
- (2)
- (1)
- (1)
- (2)
- (2)
- (1)
- (2)
- (2)
- (4)
- (4)
- (1)
- (2)
- (2)
- (1)
- (2)
- (4)
- (5)
- (2)
- (1)
- (3)
- (2)
- (2)
- (11)
- (2)
- (2)
- (2)
- (5)
- (5)
- (4)
- (2)
- (4)
- (2)
- (1)
- (2)
- (5)
- (2)
- (1)
- (2)
- (3)
- (2)
- (2)
- (5)
- (3)
- (2)
- (2)
- (1)
- (4)
- (3)
- (1)
- (1)
- (2)
- (2)
- (3)
- (2)
- (2)
- (3)
- (2)
- (1)
- (1)
- (5)
- (1)
- (2)
- (5)
- (5)
- (2)
- (1)
- (1)
- (2)
- (2)
- (1)
- (1)
- (7)
- (2)
- (2)
- (1)
- (3)
- (1)
- (3)
- (2)
- (5)
- (2)
- (2)
- (2)
- (2)
- (5)
- (2)
- (1)
- (6)
- (3)
- (2)
- (1)
- (5)
- (5)
- (2)
- (2)
- (1)
- (6)
- (1)
- (1)
- (1)
- (5)
- (1)
- (2)
- (4)
- (1)
- (3)
- (1)
- (1)
- (2)
- (1)
- (2)
- (1)
- (1)
- (1)
- (1)
- (2)
- (1)
- (1)
- (2)
- (2)
- (1)
- (2)
- (1)
- (1)
- (5)
- (2)
- (2)
- (1)
- (1)
- (2)
- (8)
- (4)
- (14)
- (7)
- (8)
- (1)
- (3)
- (1)
- (6)
- (1)
- (1)
- (2)
- (1)
- (1)
- (2)
- (20)
- (4)
- (5)
- (1)
- (3)
- (2)
- (1)
- (7)
- (8)
- (7)
- (1)
- (2)
- (1)
- (3)
- (5)
- (5)
- (1)
- (3)
- (1)
- (3)
- (6)
- (3)
- (3)
- (1)
- (2)
- (26)
- (54)
- (5)
- (6)
- (4)
- (6)
- (6)
- (16)
- (1)
- (129)
- (3)
- (1)
- (2)
- (5)
- (4)
- (13)
- (38)
- (3)
- (13)
- (12)
- (7)
- (1)
- (6)
- (6)
- (6)
- (1)
- (1)
- (1)
- (1)
- (1)
- (12)
- (38)
- (5)
- (1)
- (2)
- (1)
- (1)
- (12)
- (2)
- (15)
- (1)
- (1)
- (1)
- (1)
- (1)
- (1)
- (1)
- (1)
- (6)
- (15)
- (2)
- (1)
- (19)
- (3)
- (18)
- (1)
- (1)
- (1)
- (1)
- (2)
- (1)
- (29)
- (3)
- (2)
- (1)
- (2)
- (1)
- (1)
- (6)
- (1)
- (1)
- (1)
- (1)
- (44)
- (2)
- (27)
- (1)
- (73)
- (6)
- (73)
Filtered Search Results
Ibuprofen Impurity N Pharmaceutical Secondary Standard, MilliporeSigma™ Supelco™
Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards
Iopamidol Pharmaceutical Secondary Standard, MilliporeSigma™ Supelco™
Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards
p-Xylene, Pharmaceutical Secondary Standard, Certified Reference Material, MilliporeSigma™ Supelco™
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Risperidone Pharmaceutical Secondary Standard, MilliporeSigma™ Supelco™
Risperidone is a new central 5-hydroxytryptamine2 and dopamine D2 antagonist. It is used to treat agitation, aggression,and psychosis caused during demnetia. It is a neuroleptic drug. It is also an atypical antipsychotic drug which is used for treating schizophrenia.
![2-{2-[(2-Bromo-6-chlorophenyl)amino]phenyl}acetic Acid, MilliporeSigma™ Supelco™](https://assets.fishersci.com/TFS-Assets/CCG/Chemical-Structures/chemical-structure-cas-127792-23-8.jpg-250.jpg)
2-{2-[(2-Bromo-6-chlorophenyl)amino]phenyl}acetic Acid, MilliporeSigma™ Supelco™
CAS: 127792-23-8 Molecular Formula: C14H11BrClNO2 Molecular Weight (g/mol): 340.60 MDL Number: MFCD19704935 InChI Key: RABKUCPRNJPBRH-UHFFFAOYSA-N Synonym: Diclofenac impurity D (PhEur); 2-[(2-Bromo-6-chlorophenyl)amino]benzeneacetic acid IUPAC Name: 2-{2-[(2-bromo-6-chlorophenyl)amino]phenyl}acetic acid SMILES: OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Br
| CAS | 127792-23-8 |
|---|---|
| Molecular Weight (g/mol) | 340.60 |
| MDL Number | MFCD19704935 |
| SMILES | OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Br |
| Synonym | Diclofenac impurity D (PhEur); 2-[(2-Bromo-6-chlorophenyl)amino]benzeneacetic acid |
| IUPAC Name | 2-{2-[(2-bromo-6-chlorophenyl)amino]phenyl}acetic acid |
| InChI Key | RABKUCPRNJPBRH-UHFFFAOYSA-N |
| Molecular Formula | C14H11BrClNO2 |
Thiabendazole, Pharmaceutical Secondary Standard, Certified Reference Material, MilliporeSigma™ Supelco™
Thiabendazole is an orally effective broad spectrum anthelmintic and antimycotic drug with limited side-effects.Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
